Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $35.25.

Several brokerages have recently issued reports on BCYC. B. Riley dropped their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. JMP Securities lowered their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research report on Wednesday, December 18th. Stephens began coverage on Bicycle Therapeutics in a report on Friday, November 8th. They issued an "equal weight" rating and a $25.00 target price for the company. HC Wainwright lowered their price target on Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating on the stock in a report on Monday, December 16th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 31st.

Bicycle Therapeutics Price Performance

BCYC stock traded down $0.86 on Friday, reaching $13.31. 300,364 shares of the company traded hands, compared to its average volume of 345,135. The firm has a fifty day simple moving average of $18.70 and a 200-day simple moving average of $21.72. The company has a market cap of $919.00 million, a P/E ratio of -4.05 and a beta of 0.92. Bicycle Therapeutics has a one year low of $12.17 and a one year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company's revenue was down 50.0% on a year-over-year basis. During the same period last year, the company earned ($1.26) earnings per share. On average, sell-side analysts forecast that Bicycle Therapeutics will post -3.05 EPS for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, insider Santiago Arroyo sold 4,943 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the sale, the insider now owns 69,057 shares in the company, valued at $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares in the company, valued at approximately $483,141.51. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,933 shares of company stock worth $549,501 in the last three months. 8.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. JPMorgan Chase & Co. boosted its position in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Bicycle Therapeutics during the 3rd quarter valued at $10,028,000. Geode Capital Management LLC increased its stake in Bicycle Therapeutics by 79.3% in the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company's stock worth $868,000 after buying an additional 16,958 shares in the last quarter. Jane Street Group LLC raised its holdings in Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock valued at $457,000 after acquiring an additional 5,310 shares during the period. Finally, State Street Corp lifted its position in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company's stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.